Organization (Industry)
Epizyme (United States)
ClinicalTrials.gov lists Epizyme (United States) as lead sponsor of 21 trials. It has 96 active development programs and 18 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Epizyme (United States): 21 lead-sponsored trials and 1 legal-entity registration.
Disease areas (32)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 15 |
| Lymphoma, Non-Hodgkin | 15 |
| Lymphoma, Follicular | 12 |
| Sarcoma | 10 |
| Lymphoma, B-Cell | 8 |
Showing 5 of 32 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 4 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (96)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| TAZEMETOSTAT | Lymphoma | Phase 3 | 6 |
| TAZEMETOSTAT | Lymphoma, Non-Hodgkin | Phase 3 | 6 |
| TAZEMETOSTAT | Lymphoma, Follicular | Phase 3 | 5 |
| RITUXIMAB | Lymphoma, Follicular | Phase 3 | 2 |
| RITUXIMAB | Lymphoma, Non-Hodgkin | Phase 3 | 2 |
Showing 5 of 96 active programs.
Approved assets (18)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| TAZEMETOSTAT | 15 |
| RITUXIMAB | 2 |
| LENALIDOMIDE | 2 |
| Tazverik | 1 |
| DARATUMUMAB | 1 |
Showing 5 of 18 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 44% hit target (n=16) | 27% on time (n=15) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 4 |
| Advances in anatomic pathology | 1 |
| Advances in hematology | 1 |
| Blood | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 158 | 29 | 2025-03-18 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Weill Medical College of Cornell University | Co sponsors trial with | 3 |
| Bristol Myers Squibb Co | Co sponsors trial with | 2 |
| Roche (Switzerland) | Co sponsors trial with | 2 |
| American Society of Clinical Oncology | Co sponsors trial with | 1 |
| University of Wisconsin System | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (191)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-12-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-12-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-12-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 191 events.
Biomarker capability evidence (220)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| BAP1 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 220 evidence rows.
On Scientist.com
Epizyme (United States) is listed as a research supplier in the Scientist.com network.
Service areas
Epizyme provides epigenetics, cell differentiation, histone modifying enzymes, and protein expression.
- Website
- www.epizyme.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Epizyme on Scientist.com
For prices, more details, or to contact Epizyme, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.